Sareum Holdings (SAR)

 

Latest News

Issue of Options

RNS Number: 9211Z Sareum Holdings PLC 20 December 2017 (AIM: SAR) 20 December 2017 SAREUM HOLDINGS PLC ("Sareum" or the "Company") Issue of Options The Company announces that it granted on 19 December 2017 the following share options (the "Options") to Dr Tim Mitchell, Chief Executive Officer, Dr John Reader, Chief Scientific Officer and ...

Sareum announces new patent approval

Sareum announced that the Japanese Patent Office granted a patent for inventions associated with Sareum's TYK2 kinase ...

Patent Grants in Japan & China for TYK2 Inhibitors

RNS Number: 6985Z Sareum Holdings PLC 19 December 2017 (AIM: SAR) 19 December 2017 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Patent Grants in Japan and China for Sareum's TYK2 Inhibitors Sareum (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce that the Japanese Patent Office has grante...

Result of AGM

RNS Number: 3728Z Sareum Holdings PLC 14 December 2017 (AIM: SAR) 14 December 2017 Sareum Holdings plc ("Sareum" or "the Company") Results of AGM Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, advises that it held its Annual General Meeting today and all resolutions were duly passed. -Ends- For furth...

All News

DateHeadlineSource
20-12-17Issue of OptionsRNS
19-12-17Sareum announces new patent approvalStockMarketWire
19-12-17Patent Grants in Japan & China for TYK2 InhibitorsRNS
14-12-17Result of AGMRNS
14-12-17Sareum reports 'significant' year of progressStockMarketWire
14-12-17AGM StatementRNS
20-11-17Notice of AGM and Annual Report & AccountsRNS
14-11-17PlacingRNS
31-10-17Sareum notes experiment progressStockMarketWire
31-10-17Sierra Reports Preclinical Data for Chk1 InhibitorRNS
19-10-17Sareum reports maiden profit of £400,000StockMarketWire
19-10-17Final ResultsRNS
09-10-17Sierra Oncology host KOL Meeting on 12 Oct in NYRNS
18-09-17Sierra Oncology to host call on Chk1 inhibitorRNS
22-08-17Sareum profit after tax anticipated to beat expectationsStockMarketWire
22-08-17Pre-Close Trading StatementRNS
19-06-17Sareum to Present at the ICCS 2017RNS
05-06-17Sareum updates on Chk1 inhibitor trialsStockMarketWire
05-06-17Chk1 Clinical Trials UpdateRNS
31-05-17Sareum Holdings notes Sierra Oncology patentsStockMarketWire
31-05-17Sierra Oncology Granted US and EU PatentsRNS
25-05-17Sierra Oncology to Present at ASCO Annual MeetingRNS
09-05-17Sareum to Present at BioTrinity 2017RNS
09-03-17Director Deals - Sareum Holdings PLC (SAR)StockMarketWire
09-03-17Director ShareholdingRNS
20-02-17Sareum swings to H1 pretax profitStockMarketWire
20-02-17Half-year ResultsRNS
09-02-17Notice of Interim ResultsRNS
09-01-17Milestone Payment from Chk1 Licence AgreementRNS
22-12-16Result of General MeetingRNS
15-12-16Result of AGMRNS
06-12-16Directors' Remuneration & General MeetingRNS
29-11-16Sareum to Present at AACR-NCI-EORTC ConferenceRNS
21-11-16Notice of AGMRNS
02-11-16Sareum Holdings narrows FY pretax lossStockMarketWire
02-11-16Final ResultsRNS
24-10-16Sareum says TYK2 feasibility study successfulStockMarketWire
24-10-16Successful Outcome from TYK2 Feasibility StudyRNS
17-10-16Sareum notes Japan, Singapore Patent GrantsStockMarketWire
17-10-16Japan and Singapore Patent GrantsRNS

RSS feeds

  • Editorial news feed for LSE:SAR Editorial
  • Regulatory news feed for LSE:SAR Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account